content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

VistaGen Therapeutics, Inc. (VTGN)

1.64
-0.01
(-0.61%)
Sep 11, 4:00PM EDT
content_middle

VistaGen Therapeutics, Inc., a biotechnology company, focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The company has developed CardioSafe 3D, a novel three-dimensional in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in animals or humans. It is also developing and validating LiverSafe 3D, a novel three-dimensional in vitro bioassay system for assessing liver toxicity and drug metabolism issues. In addition, the company product candidates include AV-101, an orally available small molecule that has completed Phase 1 development for the treatment of neurological disease and disorders market, including neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Previous Close: 
1.65
Open: 
1.67
Bid: 
1.60
Ask: 
1.76
1yr Target Price: 
23.50
Day's Range: 
1.62 - 1.68
52wk Range: 
1.56 - 4.69
Volume: 
33872
Average Daily Volume: 
52389
Market Capitalization: 
15.38M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
9380000M